BeiGene Presents Clinical Results of Tislelizumab in Relapsed/Refractory Classical Hodgkin’s Lymphoma at the 60th American Society of Hematology Annual Meeting
03 déc. 2018 14h15 HE
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting
03 déc. 2018 07h30 HE
|
Onconova Therapeutics, Inc.
Overall response rate (ORR) of 90% reported in this multi-institutional Phase 2 study in hypomethylating agent (HMA) naïve patients, including Complete Remission (CR) rate of 34% ORR of 54% and...
uniQure Announces Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 and Confirms Dose for AMT-061 Pivotal Study in Hemophilia B
03 déc. 2018 07h00 HE
|
uniQure Inc.
-- Clinical Benefit of AMT-060 Maintained in All Patients Through up to Two and a Half Years of Follow-up – -- Second Dose Cohort Demonstrated a 93% Reduction in FIX Replacement Therapy Usage During...
Cellworks AI-Driven Biosimulation Predicted Chemo-resistance in AML and MDS Patients with 90% Accuracy
02 déc. 2018 21h00 HE
|
Cellworks Group, Inc.
SAN DIEGO, Dec. 02, 2018 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a leader in Precision Medicine and a global pioneer of Therapy Response Index (TRI) technology, today announced that results from...
BeiGene Announces Clinical Results of Zanubrutinib in Mantle Cell Lymphoma From Two Presentations at the 60th American Society of Hematology Annual Meeting
01 déc. 2018 15h45 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Dec. 01, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
ExCellThera announces clinical trial results using ECT-001 to be presented at ASH 2018 annual meeting
08 nov. 2018 07h05 HE
|
ExCellThera
MONTREAL, Nov. 08, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today...
Onconova Announces Four Presentations from Rigosertib Clinical Trials in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting & Exposition
05 nov. 2018 08h30 HE
|
Onconova Therapeutics, Inc.
Oral presentation on Saturday will feature efficacy and safety data from Expanded Phase 2 trial of rigosertib in combination with AzacitidineThree Poster presentations to feature pharmacokinetics,...